TP53 and cancer: Similarly, we noted a co‐occurrence of oncogenic RNF43 frameshift mutations with mutations in TP53 or senescence‐associated genes in human cancer (Appendix Table S1), suggesting that TP53 inactivation might be required to bypass an oncogenic stress‐induced growth arrest.